健脾降逆灵配合化疗治疗晚期非小细胞肺癌129例临床探讨

Clinical Effect of Jianpijiangnilin Combined with Chemotherapy on Advanced Non-small-cell Lung Cancer

目的:观察健脾降逆灵配合化疗治疗晚期非小细胞肺癌的临床疗效。方法:采用随机对照法将129例患者分为治疗组和对照组,治疗组在化疗的基础上加用中药健脾降逆灵,治疗4个疗程,观察患者临床疗效、生存期、生活质量、体重、不良反应。结果:加用健脾降逆灵在近期疗效和生存期上无统计学差异,在改善生活质量和体重方面有统计学差异,P<0.05和P<0.01;在对患者化疗后恶心呕吐症状缓解率与对照组比较显示差异有统计学意义P<0.05,而腹泻、便秘等症状由于发生率较小,两组比较无显著性差异;在骨髓抑制方面对照组较为显著,白细胞下降尤以Ⅲ度为甚,明显高于治疗组,两者比较显示差异有统计学意义P<0.05;对照组血红蛋白下降以Ⅰ～Ⅱ度为主,明显高于治疗组两者比较显示差异有统计学意义P<0.05。两组对血小板的影响差异不大。结论:健脾降逆灵配合化疗治疗晚期非小细胞肺癌既可以改善患者生活质量增加体重,又可以减轻化疗引起的消化道反应和骨髓抑制。

Objective： To study the clinical efficacy of Jianpijiangniling combined with chemotherapy for advanced non-small-cell lung cancer （NSCLC）. Methods： A total of 129 patients were randomly assigned to the treatment group and the control group. All patients received four cycles of chemotherapy. Patients in the treatment group received concurrent four-cycle Jianpijiangniling therapy. Clinical curative effect, overall survival, quality of life, body weight, and side effects were analyzed. Results： No significant difference was found in the total efficiency between the two groups. Patients＇ quality of life and body weight in the treatment group were superior to those in the control group （P〈0.05, P〈0.01）. Nausea and vomiting were more frequently seen in the control group than in the treatment group （P〈0.05）. No statistically significance was found in the rates of diarrhea, constipation, and other adverse effects between the two groups. Marrow suppression was frequently seen in the control group. The rates of leucopenia and decrease in hemoglobin were higher in the control group （P〈0.05）. The difference in the rate of thrombocytopenia between the two groups was not significant. Conclusion： Jianpijiangniling combined with chemotherapy is effective for advanced non-small-cell lung cancer, with fewer side effects.